Hospitals face growing pressure to prevent infections, and Bactiguard’s coating technology could see more demand as major device partners roll it out across more products and markets. The upside comes with real risks, including long rollout timelines and reliance on a handful of partners that can make results lumpy.Read more
Catalysts About Bactiguard Holding Bactiguard Holding licenses and sells coating and wound care technology aimed at reducing medical device related infections. What are the underlying business or industry changes driving this perspective?Read more
Catalysts About Bactiguard Holding Bactiguard Holding develops and licenses infection prevention coating technology and wound care products to global MedTech partners. What are the underlying business or industry changes driving this perspective?Read more
No trending discussion available.
Bactiguard Holding AB (publ), a medTech company, provides infection prevention technology and solutions in orthopedics, cardiology, neurology, urology, and vascular access areas. The company also has a portfolio of wound management products, such as Hydrocyn Aqua, an antimicrobial solution and gel for acute, chronic, and infected wounds; and surgical sutures comprising non-absorbable, natural absorbable, synthetic absorable, and specialty sutures. It also operates through license partnerships with global MedTech companies that apply the technology to medical devices and sell them under own brand and co-branded. The company has licensed partnership with Becton, Dickinson & Company for urinary catheter bardex IC and lubrisil IC; Well Lead Medical for catheters and tubes; and Zimmer Biomet for orthopedic trauma implants. It operates in the United States, Sweden, Malaysia, India, Bangladesh, Indonesia, the Kingdom of Saudi Arabia, and internationally. The company was founded in 2005 and is headquartered in Stockholm, Sweden.
